ISTA Pharmaceuticals Announces Conference Call and Webcast of Fourth Quarter and Full-Year 2011 Fina

ISTA Pharmaceuticals Announces Conference Call and Webcast of Fourth Quarter and Full-Year 2011 Financial Results

ID: 112785

(firmenpresse) - IRVINE, CA -- (Marketwire) -- 02/09/12 -- ISTA Pharmaceuticals, Inc. (NASDAQ: ISTA) today announced it will release fourth quarter and full-year 2011 financial results after market on February 23, 2012. In conjunction, the Company will host a conference call at 4:30 p.m. Eastern Time focusing on its corporate and commercial activities and pipeline progress.

Date: Thursday, February 23, 2012
Time: 4:30 p.m. Eastern Time

Conference call access:
Internet:
Domestic dial-in: 866-783-2138
International dial-in: 857-350-1597
Passcode: 14161724

To access the 24-hour audio replay, U.S. and Canadian participants may dial 888-286-8010; international participants may dial 617-801-6888. The access code for the replay is 52781126. This conference call also will be webcast live and archived on ISTA's website until March 23, 2012.

ISTA Pharmaceuticals, Inc. is a fast growing and the third largest branded prescription eye care business in the United States with an expanding focus on allergy therapeutics. ISTA currently markets four products, including treatments for ocular inflammation and pain post-cataract surgery, glaucoma and ocular itching associated with allergic conjunctivitis. The company's development pipeline contains additional candidates in various stages of development to treat dry eye, ocular inflammation and pain, and nasal allergies. Headquartered in Irvine, California, ISTA generated revenues of $156.5 million in 2010. For additional information about ISTA, please visit the corporate website at .



For Investor Relations:
Lauren Silvernail
949-788-5302


Jeanie Herbert
949-789-3159


Kathy Galante
Burns McClellan
212-213-0006


For General Media:
Justin Jackson
Burns McClellan
212-213-0006



Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
drucken  als PDF  an Freund senden  Aeolus' AEOL 10150 Protects Lung Tissue From Radiation by Modulating PTEN Levels, Reducing Oxidative Stress and Apoptosis Results From Phase I Clinical Trials Demonstrate Positive Safety Data of AVI BioPharma's RNA-Based Therapeutics for Treatment of Ebola and Marburg Viruses
Bereitgestellt von Benutzer: MARKETWIRE
Datum: 09.02.2012 - 12:30 Uhr
Sprache: Deutsch
News-ID 112785
Anzahl Zeichen: 0

contact information:
Town:

IRVINE, CA



Kategorie:

Biotech



Diese Pressemitteilung wurde bisher 187 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"ISTA Pharmaceuticals Announces Conference Call and Webcast of Fourth Quarter and Full-Year 2011 Financial Results"
steht unter der journalistisch-redaktionellen Verantwortung von

ISTA Pharmaceuticals (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von ISTA Pharmaceuticals



 

Werbung



Facebook

Sponsoren

foodir.org The food directory für Deutschland
News zu Snacks finden Sie auf Snackeo.
Informationen für Feinsnacker finden Sie hier.

Firmenverzeichniss

Firmen die firmenpresse für ihre Pressearbeit erfolgreich nutzen
1 2 3 4 5 6 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z